Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical therapeutics, 2008 - Elsevier
Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
[引用][C] Ramelteon 8 mg/d Versus Placebo in Patients with Chronic Insomnia: Post Hoc Analysis of a 5-Week Trial Using 50% or Greater Reduction in Latency to …
L MINI, S WANG-WEIGAND, J ZHANG - Clinical therapeutics, 2008 - pascal-francis.inist.fr
Ramelteon 8 mg/d Versus Placebo in Patients with Chronic Insomnia : Post Hoc Analysis of
a 5-Week Trial Using 50% or Greater Reduction in Latency to Persistent Sleep as a …
a 5-Week Trial Using 50% or Greater Reduction in Latency to Persistent Sleep as a …
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: Post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical Therapeutics, 2008 - infona.pl
Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: Post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical Therapeutics, 2008 - clinicaltherapeutics.com
Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical Therapeutics, 2008 - europepmc.org
Background Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective The aim of this post hoc …
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical therapeutics, 2008 - pubmed.ncbi.nlm.nih.gov
Background Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective The aim of this post hoc …
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: Post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical Therapeutics, 2008 - infona.pl
Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …